Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib

Table 4 Univariate and multivariate analysis of the factors associated with a 16-week “clinical benefit” as defined by the presence of partial response or stable disease at imaging, according to modified Response Evaluation Criteria in Solid Tumors criteria

Variable	Univariate analysis		Multivariate analysis
	OR (95%CI)	P value	OR (95%CI)	P value
ECOG
0	1 (ref.)	0.013	2	2
1-2	0.18 (0.05-0.70)
Cirrhosis etiology
Non-viral	1 (ref.)	0.040	1 (ref.)	0.043
HCV or HBV1	0.23 (0.06-0.94)		0.21 (0.05-0.95)
HCV infection
Absent	1 (ref.)	0.032	2	2
Present	0.24 (0.07-0.88)
BCLC class
B	1 (ref.)	0.003	1 (ref.)	0.004
C	0.12 (0.03-0.48)		0.10 (0.02-0.49)
Previous therapy
No	1 (ref.)	0.172	2	2
Yes	0.42 (0.12-1.45)
AFP (ng/mL)
≤ 400	1 (ref.)	0.069	2	2
> 400	0.28 (0.07-1.10)

¹Including patients with other concurrent etiologies;

²Removed during the stepwise variable selection, not included in the final multivariate model. AFP: Alpha-fetoprotein; HCV: Hepatitis C virus; HBV: Hepatitis B virus; ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona clinic liver cancer.